STOCKHOLM, May 7, 2020 /PRNewswire/ -- Nasdaq
Stockholm's listing committee has
decided that IRRAS AB (publ) ("IRRAS" or the
"Company") fulfills the requirements for admission to trading of
the Company's shares on the main market Nasdaq Stockholm subject to
customary provisions[1]. The
first day of trading of IRRAS' shares on Nasdaq
Stockholm is expected to be
Wednesday, 20 May 2020. The last day of trading of IRRAS'
shares on Nasdaq First North Premier Growth Market is expected to
occur on
Tuesday, 19 May 2020.
The shares that will be admitted to trading will be traded under
the same tickers (IRRAS) and with the same ISIN code SE0008321202
as before. No new shares will be issued in connection with the
listing on Nasdaq Stockholm Main Market. Shareholders of IRRAS do
not need to take any action in connection with the change of
listing venue.
"Following our recent capital raise in April, we are now in a
strong financial position to continue the growth of IRRAS toward
our goal of becoming a global leader in neurocritical care. It
has been our stated ambition to carry out a change of listing venue
to Nasdaq Stockholm Main Board during 2020 to raise the company's
profile and deliver shareholder value, and this transition will
further strengthen the quality associated with IRRAS," said
Kleanthis G. Xanthopoulos, Ph.D.,
President & CEO of IRRAS.
"IRRAS is now well positioned to invest further in the
commercialization of our IRRAflow and Hummingbird ICP
monitoring product lines," said Will
Martin, Chief Commercial Officer of IRRAS. "During the
COVID-19 pandemic, our innovative products have continued to
provide lifesaving treatment to critically ill patients around the
globe, and, as the economy recovers, we are ready to continue the
acceleration of our global launch."
For further information, please refer to the prospectus prepared
in connection with the admission of trading of the Company's shares
on Nasdaq Stockholm, which is expected to be approved and
registered by the Swedish Financial Supervisory Authority as well
as published on IRRAS's website (www.irras.com) on or about
May 19 2020.
[1]The approval is subject to customary
conditions, including the approval and registration of a prospectus
by the Swedish Financial Supervisory Authority, confirmation that
the dispersion requirements in respect of the shares are fulfilled
and that the Company submits the application for admission of
trading of its shares on Nasdaq Stockholm.
Advisors
In conjunction with the listing, Carnegie Investment Bank acted
as financial adviser and Setterwalls Advokatbyrå as legal adviser
to the Company.
About IRRAS
IRRAS is a global medical care company focused on delivering
innovative medical solutions to improve the lives of critically ill
patients. IRRAS designs, develops, and commercializes neurocritical
care products that transform patient outcomes and decrease the
overall cost of care by addressing complications associated with
current treatment methodologies. IRRAS markets and sells its
comprehensive, innovative IRRAflow and Hummingbird ICP
Monitoring product lines to hospitals worldwide through its direct
sales organization in the United
States and select European countries as well as an
international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in
Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq First North Premier Growth
Market (ticker: IRRAS). Redeye AB is certified adviser of the
company with email, certifiedadviser@redeye.se, or phone +46 8
121 576 90.
For more information, please contact:
USA
Kleanthis G. Xanthopoulos, Ph.D.
President and CEO
ir@irras.com
Europe
Sabina Berlin
CFO
+46-73-951-95-02
sabina.berlin@irras.com
This information is information that IRRAS is obliged to
disclose pursuant to the EU Market Abuse Regulation. The
information was released for public disclosure, through the agency
of the contact person above, on May 7,
2020 at 17:30 (CET).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/irras/r/irras-to-list-on-nasdaq-stockholm,c3106763
The following files are available for download:
https://mb.cision.com/Main/16550/3106763/1243976.pdf
|
IRRAS to list on
Nasdaq Stockholm
|
View original
content:http://www.prnewswire.com/news-releases/irras-to-list-on-nasdaq-stockholm-301055059.html
SOURCE IRRAS